When considering the preliminary evidence of clinical efficacy of carnosine in T2DM patients on insulin resistance, AGEs, and TNF-α, future clinical studies should be conducted in T2DM patients with MCI to better understand the therapeutic potential of carnosine against cognitive decline. This evidence concerns the gene TNF and type 2 diabetes mellitus.